1. Волков И.К. Медикаментозная терапия кашля у детей. Педиатрия. Журн. им. Г.Н.Сперанского. 2011; 6: 71–6.
2. Геппе Н.А., Снегоцкая М.Н. Вопросы дифференциальной диагностики и терапии кашля у детей. Cons. Med. Педиатрия (Прил.). 2006; 2: 19–22.
3. Шмелев Е.И. Кашель при воспалительных заболеваниях легких: диагностика и лечение. Cons. Med. Болезни органов дыхания (Прил.). 2007; 1: 3–8.
4. Геппе Н.А., Малахов А.Б. Муколитические и противокашлевые средства в практике педиатра (лекция). Детский доктор. 1999; 4: 42–5.
5. Самсыгина Г.А. Лечение кашля у детей. Педиатрия. Журн. им. Г.Н.Сперанского. 2004; 3: 84–92.
6. Клиническая фармакология по Гудману и Гилману. М.: Практика, 2006.
7. Smith SM, Schroeder K, Fahey T. Over-the-counter (OTC) medications for acute cough in children and adults in ambulatory settings. Cochrane Database Syst Rev 2012. CD001831.
8. Чучалин А.Г. Рациональная фармакотерапия заболеваний органов дыхания. М: Литтерра, 2013.
9. Malerba M, Ragnoli B. Ambroxol in the 21st century: pharmacological and clinical update. Exp Opin Drug Metab Toxicol 2008; 
4 (8): 1119–29.
10. Liu J, Chen X, Hu Y et al. Quantification of the major metabolites of bromhexine in human plasma using RRLC-MS/MS and its application to pharmacokinetics. Pharm Biomed Anal 2010; 51 (5): 1134–41.
11. Seifart C, Clostermann U, Seifart U et al. Cell-specific modulation of surfactant proteins by ambroxol treatment. Toxicol Appl Pharmacol 2005; 203 (1): 27–35.
12. Ottonello L, Arduino N, Bertolotto M et al. In vitro inhibition of human neutrophil histotoxicity by ambroxol: evidence for a multistep mechanism. Br J Pharmacol 2003; 140 (4): 736–42.
13. Wiessmann KJ, Niemeyer K. Clinical results in the treatment of chronic obstructive bronchitis with ambroxol in comparison with bromhexine. Arzneimittelforschung 1978; 28 (5a): 918–21.
14. Малахов А.Б., Геппе Н.А., Старостина Л.С. и др. Современные подходы к диагностике и лечению заболеваний, сопровождающихся синдромом бронхиальной обструкции в раннем детском возрасте. Трудный пациент. 2011; 9 (4): 3–7.
15. Nemcekova E, Nosalova G, Franova S. Ambroxol and protective reflexes of the respiratory tract. Bratisl Lek Listy 1998; 99 (2): 111–5.
16. Gaida W, Klinder K, Arndt K, Weiser T. Ambroxol, a Nav1,8-preferring Na (+) channel blocker, effectively suppresses pain symptoms in animal models of chronic, neuropathic and inflammatory pain. Neuropharmacology 2005; 49 (8): 1220–7.
17. Weiser T. Comparison of the effects of four Na+ channel analgesics on TTX-resistant Na+ currents in rat sensory neurons and recombinant Nav1,2 channels. Neurosci Lett 2006; 395 (3): 179–84.
18. Kamei J, Nakanishi Y, Ishikawa Y et al. Possible involvement of tetrodotoxin-resistant sodium channels in cough reflex. Eur J Pharmacol 2011; 652 (1–3): 117–20.
19. Ma YT, Tian YP, Su JL et al. Influence of ambroxol on paraquat-induced lung tissue injury and change of pulmonary surfactant-associated protein A in the experimental rats. Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi 2006; 24 (6): 348–51.
20. Proud D. Upper airway viral infections. Pulm Pharmacol Ther 2008; 21 (3): 468–73.
21. Kido H, Okumura Y, Yamada H et al. Secretory leukoprotease inhibitor and pulmonary surfactant serve as principal defenses against influenza. A virus infection in the airway and chemical agents up-regulating their levels may have therapeutic potential. Biol Chem 2004; 385 (11): 1029–34.
22. Fraschini F, Scaglione F, Scarpazza G et al. Effect of mucolytic agent on the bioavailability of antibiotics in patients with chronic respiratory diseases. Cur Ther Res 1988; 13: 734–42.
23. Spátola J, Poderoso JJ, Wiemeyer JC et al. Influence of ambroxol on lung tissue penetration of amoxicillin. Arzneimittelforschung 1987; 37 (8): 965–6.
24. Principi N, Zavattini G, Daniotti S. Possibility of interaction among antibiotics and mucolytics in children. Int J Clin Pharmacol Res 1986; 6 (5): 369–72.

А.Б.Малахов, И.А.Дронов

ГБОУ ВПО Первый МГМУ им. И.М.Сеченова Минздрава России